KEGG   DRUG: Insulin glulisineHelp
Entry
D04540                      Drug                                   

Name
Insulin glulisine (USAN/INN);
Insulin glulisine (genetical recombination) (JAN);
Apidra (TN)
Product
Formula
C258H384N64O78S6
Exact mass
5818.6373
Mol weight
5822.5816
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn (Disulfide bridge: 6-11)
(B chain) Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr
(Disulfide bridge: A7-B7; A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin and analogue
  DG01801  Insulin analogue
   DG01796  Insulin analogue, fast-acting
Cyp inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 
ATC code: 
Activity
Antidiabetic, Insulin receptor agonist
Comment
Insulin analog
Treatment of type 1 and type 2 diabetes
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
Insulin signaling pathway
Type II diabetes mellitus
Aldosterone-regulated sodium reabsorption
Interaction
CYP induction: CYP1A2 [HSA:1544]
Drug interaction
Structure map
Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB06 Insulin glulisine
      D04540  Insulin glulisine (USAN/INN)
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin glulisine
    D04540  Insulin glulisine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04540  Insulin glulisine (USAN/INN); Insulin glulisine (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Receptor tyrosine kinase
   RTK class II (Insulin receptor family)
    insulin receptor
     Insulin glulisine
      D04540  Insulin glulisine (USAN/INN)
Cytochrome P450 interactions [BR:br08309]
 CYP inducers
  CYP1A2
   Insulin glulisine
    D04540  Insulin glulisine (USAN/INN)
Antidiabetics [br08361.html]
 D04540
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D04540
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04540
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04540
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04540
BRITE hierarchy
Other DBs
CAS: 
207748-29-6
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system